Equillium (EQ) Revenue (2023 - 2024)
Equillium (EQ) reported Revenue of $4.4 million for Q4 2024, down 52.32% year-over-year from $9.2 million in Q1 2024, and down 63.88% quarter-over-quarter from $12.2 million in Q3 2024.
Equillium (EQ) Revenue (2023 - 2024) Analysis & Trends
Equillium (EQ) has 2 years of Revenue data on file, last reported at $4.4 million in Q4 2024.
- Revenue for Q4 2024 came in at $4.4 million, down 52.32% year-over-year; the trailing twelve-month figure through Sep 2025 was $4.4 million (down 90.43% YoY), and the FY2024 annual result was $41.1 million, up 13.89% from the prior year.
- Revenue fell to $4.4 million in Q4 2024 per EQ's latest filing, from $12.2 million in the prior quarter.
- Over five years, Revenue peaked at $13.9 million in Q2 2024 and troughed at $4.4 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 5.21 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 306.30 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 2.99 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Equillium | 293.17 Mn | 232.78 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 4.39 Mn |
| Sep 30, 2024 | 12.16 Mn |
| Jun 30, 2024 | 13.85 Mn |
| Mar 31, 2024 | 10.69 Mn |
| Dec 31, 2023 | 9.21 Mn |
| Sep 30, 2023 | 8.87 Mn |
| Jun 30, 2023 | 9.12 Mn |
| Mar 31, 2023 | 8.88 Mn |